101
|
Chen J, Guan Z, Dong N, Li X. A novel LC-MS/MS method for the determination of ziritaxestat in rat plasma and its pharmacokinetic study. Biomed Chromatogr 2020; 34:e4863. [PMID: 32329073 DOI: 10.1002/bmc.4863] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2020] [Revised: 04/12/2020] [Accepted: 04/20/2020] [Indexed: 11/07/2022]
Abstract
Ziritaxestat is a first-in-class autotoxin inhibitor. The purpose of this study was to develop a liquid chromatography/electrospray ionization tandem mass spectrometric (LC-MS/MS) method for the determination of ziritaxestat in rat plasma. The plasma sample was deproteinated using acetonitrile and then separated on an Acquity BEH C18 column with water containing 0.1% formic acid and acetonitrile as mobile phase, which was delivered at 0.4 ml/min. Ziritaxestat and the internal standard (crizotinib) were quantitatively monitored with precursor-to-product transitions of m/z 589.3 > 262.2 and m/z 450.1 > 260.2, respectively. The total running time was 2.5 min. The method showed excellent linearity over the concentration range 0.5-2000 ng/ml, with correlation coefficient >0.9987. The extraction recovery was >82.09% and the matrix effect was not significant. Inter- and intra-day precisions (RSD) were <11.20% and accuracies were in the range of -8.50-7.45%. Ziritaxestat was demonstrated to be stable in rat plasma under the tested conditions. The validated LC-MS/MS method was successfully applied to study the pharmacokinetic profiles of ziritaxestat in rat plasma after intravenous and oral administration. Pharmacokinetic results demonstrated that ziritaxestat displayed a short half-life (~3 h) and low bioavailability (20.52%).
Collapse
Affiliation(s)
- Jing Chen
- Department of Gastroenterology, The First People's Hospital of Lianyungang, Lianyungang, Jiangsu Province, China
| | - Zhenhua Guan
- Department of Gastroenterology, The First People's Hospital of Lianyungang, Lianyungang, Jiangsu Province, China
| | - Na Dong
- Department of Nursing, Hebei Women's Vocational College, Shijiazhuang, Hebei Province, China
| | - Xueliang Li
- Department of Gastroenterology, The First People's Hospital of Lianyungang, Lianyungang, Jiangsu Province, China
- Department of Gastroenterology, The First Clinical Medical College of Nanjing Medical University, Nanjing, Jiangsu Province, China
| |
Collapse
|
102
|
Cornelissen AS, Klaassen SD, van Groningen T, Bohnert S, Joosen MJA. Comparative physiology and efficacy of atropine and scopolamine in sarin nerve agent poisoning. Toxicol Appl Pharmacol 2020; 396:114994. [PMID: 32251685 DOI: 10.1016/j.taap.2020.114994] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2019] [Revised: 03/30/2020] [Accepted: 04/02/2020] [Indexed: 01/20/2023]
Abstract
Anticholinergic treatment is key for effective medical treatment of nerve agent exposure. Atropine is included at a 2 mg intramuscular dose in so-called autoinjectors designed for self- and buddy-aid. As patient cohorts are not available, predicting and evaluating the efficacy of medical countermeasures relies on animal models. The use of atropine as a muscarinic antagonist is based on efficacy achieved in studies in a variety of species. The dose of atropine administered varies considerably across these studies. This is a complicating factor in the prediction of efficacy in the human situation, largely because atropine dosing also influences therapeutic efficacy of oximes and anticonvulsants generally part of the treatment administered. To improve translation of efficacy of dosing regimens, including pharmacokinetics and physiology provide a promising approach. In the current study, pharmacokinetics and physiological parameters obtained using EEG and ECG were assessed in naïve rats and in sarin-exposed rats for two anticholinergic drugs, atropine and scopolamine. The aim was to find a predictive parameter for therapeutic efficacy. Scopolamine and atropine showed a similar bioavailability, but brain levels reached were much higher for scopolamine. Scopolamine exhibited a dose-dependent loss of beta power in naïve animals, whereas atropine did not show any such central effect. This effect was correlated with an enhanced anticonvulsant effect of scopolamine compared to atropine. These findings show that an approach including pharmacokinetics and physiology could contribute to improved dose scaling across species and assessing the therapeutic potential of similar anticholinergic and anticonvulsant drugs against nerve agent poisoning.
Collapse
Affiliation(s)
- Alex S Cornelissen
- TNO Defense, Security and Safety, CBRN Protection, Lange Kleiweg 137, 2288, GJ, Rijswijk, the Netherlands.
| | - Steven D Klaassen
- TNO Defense, Security and Safety, CBRN Protection, Lange Kleiweg 137, 2288, GJ, Rijswijk, the Netherlands
| | - Tomas van Groningen
- TNO Defense, Security and Safety, CBRN Protection, Lange Kleiweg 137, 2288, GJ, Rijswijk, the Netherlands
| | - Sara Bohnert
- Defence Research and Development Canada-Suffield Research Centre, Department of National Defence, Suffield, Alberta, Canada
| | - Marloes J A Joosen
- TNO Defense, Security and Safety, CBRN Protection, Lange Kleiweg 137, 2288, GJ, Rijswijk, the Netherlands
| |
Collapse
|
103
|
Investigation of drug partition kinetics to fat in simulated fed state gastric conditions based on drug properties. Eur J Pharm Sci 2020; 146:105263. [DOI: 10.1016/j.ejps.2020.105263] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2019] [Revised: 02/09/2020] [Accepted: 02/10/2020] [Indexed: 02/08/2023]
|
104
|
Finlay DB, Duffull SB, Glass M. 100 years of modelling ligand-receptor binding and response: A focus on GPCRs. Br J Pharmacol 2020; 177:1472-1484. [PMID: 31975518 PMCID: PMC7060363 DOI: 10.1111/bph.14988] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2019] [Revised: 11/21/2019] [Accepted: 12/04/2019] [Indexed: 12/21/2022] Open
Abstract
Experimental pharmacologists rely on the application of models to describe biological observations in order to learn about a drug's effective concentration, the strength with which it binds its target and drives a response (at either molecular or system level), and the nature of more complex drug actions (allosterism/functional selectivity). Models in current use build upon decades of basic principles, going back to the beginning of the last century. Yet often, researchers are only partially familiar with these underlying principles, creating the potential for confusion due to failure to recognise the underpinning assumptions of the models that are used. Here, we describe the history of receptor theory as it underpins receptor stimulus-response models in use today, emphasising particularly attributes and models relevant to GPCRs-and point to some current aims of model development.
Collapse
Affiliation(s)
- David B. Finlay
- Department of Pharmacology and ToxicologyUniversity of OtagoDunedinNew Zealand
| | - Stephen B. Duffull
- Otago Pharmacometrics Group, School of PharmacyUniversity of OtagoDunedinNew Zealand
| | - Michelle Glass
- Department of Pharmacology and ToxicologyUniversity of OtagoDunedinNew Zealand
| |
Collapse
|
105
|
Abstract
In community settings, negative symptoms and cognitive deficits are the primary barriers to independent living, stable relationships, and employment for individuals suffering from schizophrenia-spectrum disorders. In contrast, however, positive psychotic symptoms (e.g., command hallucinations and persecutory delusions) often drive behavior which serves as the gateway to arrest and criminalization. Historically, the keystone of treatment for positive psychotic symptoms has been antagonism of dopamine D2 receptors in the mesolimbic tract. In this article, we review and explore the principles underlying dopamine antagonism for the treatment of psychosis; optimization of dopamine antagonists in treating positive psychotic symptoms; the advantages of depot dopamine antagonist antipsychotics in forensic settings; the concepts of pharmacokinetic and pharmacodynamic treatment failures; and the role of medication plasma concentrations in optimizing and managing treatment.
Collapse
|
106
|
Bracke N, Janssens Y, Wynendaele E, Tack L, Maes A, van de Wiele C, Sathekge M, de Spiegeleer B. Blood-brain barrier transport kinetics of NOTA-modified proteins: the somatropin case. THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING : OFFICIAL PUBLICATION OF THE ITALIAN ASSOCIATION OF NUCLEAR MEDICINE (AIMN) [AND] THE INTERNATIONAL ASSOCIATION OF RADIOPHARMACOLOGY (IAR), [AND] SECTION OF THE SOCIETY OF... 2020; 64:105-114. [PMID: 29697217 DOI: 10.23736/s1824-4785.18.03025-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
BACKGROUND Chemical modifications such as PEG, polyamine and radiolabeling on proteins can alter their pharmacokinetic behavior and their blood-brain barrier (BBB) transport characteristics. NOTA, i.e. 1,4,7-triazacyclononane-1,4,7-triacetic acid, is a bifunctional chelating agent that has attracted the interest of the scientific community for its high complexation constant with metals like gallium. Until now, the comparative BBB transport characteristics of NOTA-modified proteins versus unmodified proteins are not yet described. METHODS Somatropin (i.e. recombinant human growth hormone), NOTA-conjugated somatropin and gallium-labelled NOTA-conjugated somatropin were investigated for their brain penetration characteristics (multiple time regression and capillary depletion [CD]) in an in vivo mice model to determine the blood-brain transfer properties. RESULTS The three compounds showed comparable initial brain influx, with Kin=0.38±0.14 µL/(g×min), 0.36±0.16 µL/(g×min) and 0.28±0.18 µL/(g×min), respectively. CD indicated that more than 80% of the influxed compounds reached the brain parenchyma. All three compounds were in vivo stable in serum and brain during the time frame of the experiments. CONCLUSIONS Our results show that modification of NOTA as well as gallium chelation onto proteins, in casu somatropin, does not lead to a significantly changed pharmacokinetic profile at the blood-brain barrier.
Collapse
Affiliation(s)
- Nathalie Bracke
- Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium
| | - Yorick Janssens
- Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium
| | | | - Liesa Tack
- Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium
| | - Alex Maes
- Faculty of Medicine, Catholic University of Leuven, Leuven, Belgium
- Department of Nuclear Medicine, AZ Groeninge, Kortrijk, Belgium
| | | | - Mike Sathekge
- Department of Nuclear Medicine, Steve Biko Academic Hospital, University of Pretoria, Pretoria, South Africa
| | | |
Collapse
|
107
|
Identification and preclinical development of an anti-proteolytic uPA antibody for rheumatoid arthritis. J Mol Med (Berl) 2020; 98:585-593. [PMID: 32108909 DOI: 10.1007/s00109-020-01889-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2019] [Revised: 02/07/2020] [Accepted: 02/18/2020] [Indexed: 10/25/2022]
Abstract
Blocking the proteolytic capacity of urokinase-type plasminogen activator (uPA) with a monoclonal antibody (mAb) reduces arthritis progression in the collagen-induced mouse arthritis model to an extent that is on par with the effect of blocking tumor necrosis factor-alpha by etanercept. Seeking to develop a novel therapy for rheumatoid arthritis, a humanized mAb, NNC0266-0043, was selected for its dual inhibition of both the zymogen activation and the proteolytic capacity of human uPA. The antibody revealed nonlinear elimination kinetics in cynomolgus monkeys consistent with binding to and turnover of endogenous uPA. At a dose level of 20.6 mg kg-1, the antibody had a plasma half-life of 210 h. Plasma uPA activity, a pharmacodynamic marker of anti-uPA therapy, was reduced to below the detection limit during treatment, indicating that an efficacious plasma concentration was reached. Pharmacokinetic modeling predicted that sufficient antibody levels can be sustained in arthritis patients dosed subcutaneously once weekly. The anti-uPA mAb was also well tolerated in cynomolgus monkeys at weekly doses up to 200 mg kg-1 over 4 weeks. The data from cynomolgus monkeys and from human material presented here indicates that anti-uPA mAb NNC0266-0043 is suitable for clinical testing as a novel therapeutic for rheumatic diseases. KEY MESSAGES: Background: Anti-uPA therapy is on par with etanercept in a mouse arthritis model. A new humanized antibody blocks activation and proteolytic activity of human uPA. The antibody represents a radically novel mode-of-action in anti-rheumatic therapy. The antibody has PK/PD properties in primates consistent with QW clinical dosing.
Collapse
|
108
|
García-Varela L, Vállez García D, Rodríguez-Pérez M, van Waarde A, Sijbesma JWA, Schildt A, Kwizera C, Aguiar P, Sobrino T, Dierckx RAJO, Elsinga PH, Luurtsema G. Test-Retest Repeatability of [ 18F]MC225-PET in Rodents: A Tracer for Imaging of P-gp Function. ACS Chem Neurosci 2020; 11:648-658. [PMID: 31961646 PMCID: PMC7034080 DOI: 10.1021/acschemneuro.9b00682] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
![]()
In
longitudinal PET studies, animals are repeatedly anesthetized
which may affect the repeatability of PET measurements. The aim of
this study was to assess the effect of anesthesia on the P-gp function
as well as the reproducibility of [18F]MC225 PET scans.
Thus, dynamic PET scans with blood sampling were conducted in 13 Wistar
rats. Seven animals were exposed to isoflurane anesthesia 1 week before
the PET scan (“Anesthesia-exposed” PET). A second group
of six animals was used to evaluate the reproducibility of measurements
of P-gp function at the blood–brain barrier (BBB) with [18F]MC225. In this group, two PET scans were made with a 1
week interval (“Test” and “Retest” PET).
Pharmacokinetic parameters were calculated using compartmental models
and metabolite-corrected plasma as an input function. “Anesthesia-exposed”
animals showed a 28% decrease in whole-brain volume of distribution
(VT) (p < 0.001) compared
to “Test”, where the animals were not previously anesthetized.
The VT at “Retest” also
decreased (19%) compared to “Test” (p < 0.001). The k2 values in whole-brain
were significantly increased by 18% in “Anesthesia-exposed”
(p = 0.005) and by 15% in “Retest”
(p = 0.008) compared to “Test”. However,
no significant differences were found in the influx rate constant K1, which is considered as the best parameter
to measure the P-gp function. Moreover, Western Blot analysis did
not find significant differences in the P-gp expression of animals
not pre-exposed to anesthesia (“Test”) or pre-exposed
animals (“Retest”). To conclude, anesthesia may affect
the brain distribution of [18F]MC225 but it does not affect
the P-gp expression or function.
Collapse
Affiliation(s)
- Lara García-Varela
- Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Hanzeplein 1, P.O.
Box 30001, 9713 GZ Groningen, The Netherlands
| | - David Vállez García
- Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Hanzeplein 1, P.O.
Box 30001, 9713 GZ Groningen, The Netherlands
| | - Manuel Rodríguez-Pérez
- Clinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela 15706, Spain
| | - Aren van Waarde
- Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Hanzeplein 1, P.O.
Box 30001, 9713 GZ Groningen, The Netherlands
| | - Jürgen W. A. Sijbesma
- Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Hanzeplein 1, P.O.
Box 30001, 9713 GZ Groningen, The Netherlands
| | - Anna Schildt
- Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Hanzeplein 1, P.O.
Box 30001, 9713 GZ Groningen, The Netherlands
| | - Chantal Kwizera
- Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Hanzeplein 1, P.O.
Box 30001, 9713 GZ Groningen, The Netherlands
| | - Pablo Aguiar
- Department of Nuclear Medicine and Molecular Imaging Group, Clinical University Hospital, IDIS Health Research Institute, Santiago de Compostela 15706, Spain
| | - Tomás Sobrino
- Clinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela 15706, Spain
| | - Rudi A. J. O. Dierckx
- Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Hanzeplein 1, P.O.
Box 30001, 9713 GZ Groningen, The Netherlands
| | - Philip H. Elsinga
- Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Hanzeplein 1, P.O.
Box 30001, 9713 GZ Groningen, The Netherlands
| | - Gert Luurtsema
- Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Hanzeplein 1, P.O.
Box 30001, 9713 GZ Groningen, The Netherlands
| |
Collapse
|
109
|
Santurtun E, Navarro G, Phillips CJC. Do antiemetics attenuate the behavioural responses of sheep to simulated ship motion? Appl Anim Behav Sci 2020. [DOI: 10.1016/j.applanim.2019.104924] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
110
|
Doughty B, Tumey LN, Williams K. Case report: Albendazole associated psychosis. Ment Health Clin 2019; 9:397-400. [PMID: 31857936 PMCID: PMC6881107 DOI: 10.9740/mhc.2019.11.397] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Introduction The association of psychosis with albendazole monotherapy has not been established in current literature. Case Report We present the first reported case of acute psychosis associated with albendazole. Upon cessation of the agent and the introduction of aripiprazole, the patient's psychosis remitted, and the patient did not present for acute treatment in the months to follow. Discussion/Conclusion The temporal relationship and laboratory data support albendazole's role in leading to the aforementioned toxicity. Such reactions, although rare, can drastically impact patient care and may warrant increased provider consideration when choosing to prescribe albendazole.
Collapse
|
111
|
McGrath J, McGrath A, Burdett J, Shokri T, Cohn JE. Systemic Pharmacokinetics of Topical Intranasal Cocaine in Healthy Subjects. Am J Rhinol Allergy 2019; 34:336-341. [DOI: 10.1177/1945892419896241] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Background Topical cocaine is currently available for local anesthesia of the upper airway mucous membranes. Objective The objective of this study was to define the safety and efficacy of topical intranasal cocaine for a subsequent phase II clinical trial. Methods This study was a single-dose, single-center, and open-label study of the plasma and urinary pharmacokinetics (PK) of 4% topical cocaine and its major metabolites, benzoylecgonine (BE) and ecgonine methyl ester (EME), in 30 healthy subjects. Subjects received the topical solution on cotton pledgets containing 4 mL of 4% topical cocaine applied for 20 minutes, which was equivalent to 160 mg of cocaine hydrochloride. Results A total of 30 subjects (14 males and 16 females) were enrolled, treated, and provided PK data for analysis. Mean plasma concentrations of cocaine rose rapidly during the intranasal exposure period, with peak levels (Cmax, 37.0 ± 17.3 ng/mL) observed at the time of pledget removal (Tmax, 0.43 ± 0.34 h). Mean plasma concentrations then fell rapidly and monoexponentially for the remainder of the study, with a mean half-life (t1/2) of 1.04 ± 0.35 hours. Following a 20-minute topical intranasal exposure to a 160 mg dose of cocaine 4% solution, the mean 0 to 12 hours recoveries of cocaine, BE, and EME were 117 ± 67 μg, 816 ± 440 μg, and 275 ± 113 μg, respectively. Plotting urinary recovery by collection interval showed that urinary excretion of cocaine closely followed the time course of plasma cocaine. Conclusions Cocaine was rapidly but incompletely absorbed and then rapidly eliminated. Only 4% of the administered cocaine dose appeared to be absorbed in this study. Cocaine appeared in the urine with a time course similar to that in plasma.
Collapse
Affiliation(s)
- John McGrath
- Department of Otolaryngology-Head and Neck Surgery, Philadelphia College of Osteopathic Medicine, Philadelphia, Pennsylvania
| | - Alexa McGrath
- Philadelphia College of Osteopathic Medicine, Philadelphia, Pennsylvania
| | - Jacob Burdett
- Department of Otolaryngology-Head and Neck Surgery, Philadelphia College of Osteopathic Medicine, Philadelphia, Pennsylvania
| | - Tom Shokri
- Department of Otolaryngology-Head and Neck Surgery, Penn State Hershey Medical Center, Hershey, Pennsylvania
| | - Jason E. Cohn
- Department of Otolaryngology-Head and Neck Surgery, Philadelphia College of Osteopathic Medicine, Philadelphia, Pennsylvania
| |
Collapse
|
112
|
Oo WM, Liu X, Hunter DJ. Pharmacodynamics, efficacy, safety and administration of intra-articular therapies for knee osteoarthritis. Expert Opin Drug Metab Toxicol 2019; 15:1021-1032. [PMID: 31709838 DOI: 10.1080/17425255.2019.1691997] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Introduction: Osteoarthritis (OA) is the leading cause of disability in the elderly, usually presenting with mono-or oligo-arthritis where local drug delivery by intra-articular (IA) injection may be more effective in terms of increased bioavailability, less systemic exposure and reduced adverse events. Several intra-articular medications for symptomatic are available on the market while the new disease-modifying drugs (DMOADs) are progressing into phase 3 pipeline of drug development.Areas covered: This narrative review covered the pharmacokinetic and pharmacodynamics of clinically available IA drugs which include corticosteroids, hyaluronic acid as well as injection techniques, efficacy, adverse effects and contraindications. In addition, the authors briefly describe the newer disease-modifying OA drugs (DMOAD) which are undergoing phase 3 pipeline of development such as Fibroblast growth factor (FGF-18) and Wnt inhibitor.Expert opinion: This is a rapidly evolving area with both new products and new trials regularly emerging. It is also a critically important area in a disease field that lacks for safe and effective treatments, where intra-articular delivery may enhance both local efficacy and reduce systemic toxicity.
Collapse
Affiliation(s)
- Win Min Oo
- Rheumatology Department, Royal North Shore Hospital and Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia
| | - Xiaoqian Liu
- Rheumatology Department, Royal North Shore Hospital and Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia
| | - David J Hunter
- Rheumatology Department, Royal North Shore Hospital and Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia
| |
Collapse
|
113
|
de Mello CPP, Rumsey J, Slaughter V, Hickman JJ. A human-on-a-chip approach to tackling rare diseases. Drug Discov Today 2019; 24:2139-2151. [PMID: 31412288 PMCID: PMC6856435 DOI: 10.1016/j.drudis.2019.08.001] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2019] [Revised: 07/18/2019] [Accepted: 08/05/2019] [Indexed: 12/20/2022]
Abstract
Drug development for rare diseases, classified as diseases with a prevalence of < 200 000 patients, is limited by the high cost of research and low target population. Owing to a lack of representative disease models, research has been challenging for orphan drugs. Human-on-a-chip (HoaC) technology, which models human tissues in interconnected in vitro microfluidic devices, has the potential to lower the cost of preclinical studies and increase the rate of drug approval by introducing human phenotypic models early in the drug discovery process. Advances in HoaC technology can drive a new approach to rare disease research and orphan drug development.
Collapse
Affiliation(s)
| | | | - Victoria Slaughter
- NanoScience Technology Center, University of Central Florida, Orlando, FL 32826, USA
| | - James J Hickman
- NanoScience Technology Center, University of Central Florida, Orlando, FL 32826, USA; Hesperos, Inc., Orlando, FL 32826, USA.
| |
Collapse
|
114
|
Diez Bernal S, Studer N, Thormann W, Spadavecchia C, Levionnois O. Pharmacokinetic-pharmacodynamic modelling of the antinociceptive effect of a romifidine infusion in standing horses. Vet Anaesth Analg 2019; 47:129-136. [PMID: 31810766 DOI: 10.1016/j.vaa.2019.06.010] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2019] [Revised: 05/16/2019] [Accepted: 06/18/2019] [Indexed: 01/23/2023]
Abstract
OBJECTIVE To evaluate the effect of a romifidine infusion on antinociception and sedation, and to investigate its relationship with plasma concentration. STUDY DESIGN Prospective, experimental, nonrandomized trial. ANIMALS A total of 10 healthy adult warmblood horses. METHODS Romifidine (loading dose: 0.08 mg kg-1, infusion: 0.03 mg kg-1 hour-1) was administered intravenously over 120 minutes. Romifidine plasma concentrations were determined by capillary electrophoresis. Sedation quality and nociceptive thresholds were evaluated at regular time points before, during and after romifidine administration. The nociceptive withdrawal reflex was elicited by electrical stimulation at the thoracic limb using a dedicated threshold tracking algorithm and recorded by electromyography at the deltoid muscle. A pharmacokinetic-pharmacodynamic model was established and correlation between romifidine plasma concentration and main output variables tested. RESULTS A two compartmental model best described the romifidine pharmacokinetic profile. The nociceptive thresholds increased compared with baseline in all horses from 10 to 146 minutes after romifidine administration (p < 0.001). Peak effect reached 5.7 ± 2.3 times the baseline threshold (mean ± standard deviation). The effect/concentration relationship followed a counter-clockwise hysteresis loop. The mean plasma concentration was weakly correlated to nociceptive thresholds (p < 0.0071, r = 0.392). The sedative effects were significant until 160 minutes but variable, not correlated to plasma concentration (p = 0.067), and weakly correlated to nociceptive thresholds (p < 0.0001, r = 0.33). CONCLUSIONS AND CLINICAL RELEVANCE Romifidine elicited a marked antinociceptive effect. Romifidine-induced antinociception appeared with a delayed onset and lasted longer than sedation after discontinuing its administration.
Collapse
Affiliation(s)
- Sabina Diez Bernal
- Department of Anaesthesiology and Pain Therapy, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
| | - Nicole Studer
- Department of Anaesthesiology and Pain Therapy, Vetsuisse Faculty, University of Bern, Bern, Switzerland
| | - Wolfgang Thormann
- Clinical Pharmacology Laboratory, Institute for Infectious Diseases, University of Bern, Bern, Switzerland
| | - Claudia Spadavecchia
- Department of Anaesthesiology and Pain Therapy, Vetsuisse Faculty, University of Bern, Bern, Switzerland
| | - Olivier Levionnois
- Department of Anaesthesiology and Pain Therapy, Vetsuisse Faculty, University of Bern, Bern, Switzerland
| |
Collapse
|
115
|
Physcion and physcion 8-O-β-glucopyranoside: A review of their pharmacology, toxicities and pharmacokinetics. Chem Biol Interact 2019; 310:108722. [DOI: 10.1016/j.cbi.2019.06.035] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2019] [Revised: 05/27/2019] [Accepted: 06/17/2019] [Indexed: 12/31/2022]
|
116
|
Esmieu C, Guettas D, Conte-Daban A, Sabater L, Faller P, Hureau C. Copper-Targeting Approaches in Alzheimer’s Disease: How To Improve the Fallouts Obtained from in Vitro Studies. Inorg Chem 2019; 58:13509-13527. [DOI: 10.1021/acs.inorgchem.9b00995] [Citation(s) in RCA: 42] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
| | | | | | | | - Peter Faller
- LCC−CNRS, Université de Toulouse, CNRS, Toulouse, France
| | | |
Collapse
|
117
|
Boufleur P, Sciani JM, Goldfeder M, Faria F, Branco V, Chudzinski-Tavassi AM. Biodistribution and Pharmacokinetics of Amblyomin-X, a Novel Antitumour Protein Drug in Healthy Mice. Eur J Drug Metab Pharmacokinet 2019; 44:111-120. [PMID: 30132264 DOI: 10.1007/s13318-018-0500-z] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
BACKGROUND Amblyomin-X is a recombinant protein under development for cancer treatment owing to its selective cytotoxic activity over several tumour cell lines and tumour regression in mice models. The aim of this study was to examine the distribution and pharmacokinetics of amblyomin-X in healthy female mice. METHODS Amblyomin-X was injected intravenously into the healthy animals and at controlled times plasma and organs were removed and analysed for identification and quantification of the protein. Alternatively, the labelled protein was injected into mice and tracked in an in vivo imaging system. RESULTS Amblyomin-X was rapidly eliminated from plasma, probably because of its inability to bind to plasma albumin. After 10 min, the protein was found in the thymus and lungs, and later in the heart, liver and kidneys. In the liver, the protein was found until 24 h after a single injection. The in vivo analysis showed the same kinetics profile, besides the identification of amblyomin-X in the bladder region, indicating its elimination via urine. Only fragments of amblyomin-X were observed in the urine. CONCLUSIONS These findings suggest that amblyomin-X is rapidly distributed to the tissues, metabolized by the liver or even kidneys, and eliminated in urine in healthy mice. There is no accumulation in any organ.
Collapse
Affiliation(s)
- Pamela Boufleur
- Laboratory of Molecular Biology, Butantan Institute, São Paulo, SP, Brazil
| | - Juliana Mozer Sciani
- Laboratory of Molecular Biology, Butantan Institute, São Paulo, SP, Brazil. .,Laboratório Multidisciplinar de Pesquisa, Universidade São Francisco, Av. Francisco de Assis, 218 Cidade Universitária, Bragança Paulista, SP, 12916-900, Brazil.
| | - Mauricio Goldfeder
- Laboratory of Molecular Biology, Butantan Institute, São Paulo, SP, Brazil
| | - Fernanda Faria
- Laboratory of Molecular Biology, Butantan Institute, São Paulo, SP, Brazil
| | - Vânia Branco
- Laboratory of Molecular Biology, Butantan Institute, São Paulo, SP, Brazil
| | | |
Collapse
|
118
|
Mauro M, De Grandis RA, Campos ML, Bauermeister A, Peccinini RG, Pavan FR, Lopes NP, De Moraes NV. Acid diterpenes from Copaiba oleoresin (Copaifera langsdorffii): Chemical and plasma stability and intestinal permeability using Caco-2 cells. JOURNAL OF ETHNOPHARMACOLOGY 2019; 235:183-189. [PMID: 30763698 DOI: 10.1016/j.jep.2019.02.017] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/30/2018] [Revised: 02/04/2019] [Accepted: 02/10/2019] [Indexed: 06/09/2023]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE Copaiba oleoresin has been used in folk medicine in the treatment of bronchitis, syphilis, skin diseases and ulcers due to its anti-inflammatory and antiseptic activities, but there is no information about major compounds oral absorption to support the traditional use. AIM OF STUDY Considering the potential of copalic (CA) and kaurenoic acid (KA) - major biological activity (in vitro) diterpenes found in the oleoresin, this study aimed to evaluate the intestinal permeability of CA and KA using Caco-2 cells model as predictive test for oral drug absorption. MATERIALS AND METHODS Chemical stability at pH 1.2 and 7.4 and plasma stability were evaluated to mimic physiological conditions of the gastrointestinal tract. The intestinal permeability of CA and KA was evaluated in Caco-2 cells in the presence and absence of the P-glycoprotein inhibitor verapamil. RESULTS CA and KA were rapidly degraded at pH 1.2 (0.2 M Clark-Lubs buffer). At pH 7.4 (0.1 M phosphate buffer), CA was stable for up to 24 h and KA for up to 6 h. In human plasma, CA and KA can be considered stable for 24 h and 12 h at 37 °C, respectively. Caco-2 cells were considered viable when incubated with CA or KA in the range of 3.9-250 μM for 24 h. CA and KA exhibited moderate apparent permeability (Papp) of 4.67 (±0.08) × 10-6 cm/s and 4.66 (±0.04) × 10-6 cm/s, respectively. Simultaneous incubation with verapamil showed that P-glycoprotein does not play a relevant role on CA and KA oral absorption, with Papp of 4.48 (±0.26) × 10-6 cm/s and 5.37 (±0.72) × 10-6 cm/s observed for CA and KA, respectively. CONCLUSION The oral absorption of both CA and KA is driven by mainly passive permeability, is not limited by p-glycoprotein, but enteric-coated dosage forms should be used to avoid chemical instability in the gastric pH.
Collapse
Affiliation(s)
- M Mauro
- São Paulo State University (UNESP), School of Pharmaceutical Sciences, Araraquara, SP ZIP 14801-902, Brazil.
| | - R A De Grandis
- São Paulo State University (UNESP), School of Pharmaceutical Sciences, Araraquara, SP ZIP 14801-902, Brazil.
| | - M L Campos
- Federal University of Mato Grosso, Sinop, MT, Brazil.
| | - A Bauermeister
- University of Sao Paulo (USP), NPPNS, School of Pharmaceutical Sciences of Ribeirao Preto, Ribeirao Preto, SP ZIP 14040-903, Brazil.
| | - R G Peccinini
- São Paulo State University (UNESP), School of Pharmaceutical Sciences, Araraquara, SP ZIP 14801-902, Brazil.
| | - F R Pavan
- São Paulo State University (UNESP), School of Pharmaceutical Sciences, Araraquara, SP ZIP 14801-902, Brazil.
| | - N P Lopes
- University of Sao Paulo (USP), NPPNS, School of Pharmaceutical Sciences of Ribeirao Preto, Ribeirao Preto, SP ZIP 14040-903, Brazil.
| | - N V De Moraes
- São Paulo State University (UNESP), School of Pharmaceutical Sciences, Araraquara, SP ZIP 14801-902, Brazil.
| |
Collapse
|
119
|
Offerdahl T, Mishra V. Pharmacology for the Audiologist. Semin Hear 2019; 40:87-96. [PMID: 31036986 DOI: 10.1055/s-0039-1684038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
Abstract
The purpose of this article is to provide a brief introduction and review regarding basic principles of pharmacology, including terminology and colloquialisms, as well as pharmacokinetic and pharmacodynamic principles of ototoxic agents. As an audiology practitioner, it is more important than ever to have a working knowledge regarding the known and proposed mechanisms of action for drugs and chemicals with known ototoxicity potential. Additionally, this article provides a discussion regarding the biochemistry behind distribution, which is a major step in determining ototoxic potential of known and potential ototoxins.
Collapse
Affiliation(s)
- Tracy Offerdahl
- Osborne College of Audiology, Salus University, Elkins Park, Pennsylvania
| | - Vallabhi Mishra
- Temple University School of Pharmacy, Philadelphia, Pennsylvania
| |
Collapse
|
120
|
Kung TA, Lee SH, Wang WH. Determination of sulfamonomethoxine in tilapia (Oreochromis niloticus × Oreochromis mossambicus) by liquid chromatography-tandem mass spectrometry and its application pharmacokinetics study. J Food Drug Anal 2019; 27:339-346. [PMID: 30648589 PMCID: PMC9298614 DOI: 10.1016/j.jfda.2018.08.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2018] [Revised: 08/28/2018] [Accepted: 08/29/2018] [Indexed: 12/01/2022] Open
Abstract
A precise and reliable analytical method to measure trace levels of sulfamonomethoxine (SMM) and N4-acetyl metabolite in tilapia samples using liquid chromatography-tandem mass spectrometry was developed. Optimized chromatographic separation was performed on C18 reversed-phase columns using gradient elution with methanol and 5 mmol/L of an ammonium acetate aqueous solution (adjusted to pH 3.5 using formic acid). This study investigated the pharmacokinetic properties and tissue distribution of SMM and its major metabolite N4-acetyl sulfamonomethoxine (AC-SMM) in tilapia after a single dose of 100 mg kg−1 body weight of orally administered SMM. Blood and tissues were collected between 0.5 and 192 h with 14 total sampling time points. SMM was rapidly absorbed, and extensively distributed in the bile and liver through systemic circulation. Enterohepatic circulation of SMM was observed in the tilapia body. Acetylation percentages were 45% (blood), 90% (liver), 62% (kidney), 98% (bile), and 52% (muscle). High concentrations of AC-SMM accumulated in the tilapia bile. At 192 h, AC-SMM concentration in the bile remained at 4710 μg kg−1. The ke value of AC-SMM (0.015 h−1) in the blood was lower than that of SMM (0.032 h−1). This study demonstrated effective residue monitoring and determined the pharmacokinetic properties of SMM and AC-SMM in tilapia.
Collapse
Affiliation(s)
- Te-An Kung
- Asia-Pacific Ocean Research Center, Department of Marine Biotechnology and Resources, National Sun Yat-Sen University, Kaohsiung, 80424, Taiwan; Department of Agricultural Chemistry, National Taiwan University, Taipei, 10617, Taiwan.
| | - Shu-Hui Lee
- Center of General Education, National Kaohsiung Marine University, Kaohsiung, 81157, Taiwan.
| | - Wei-Hsien Wang
- Asia-Pacific Ocean Research Center, Department of Marine Biotechnology and Resources, National Sun Yat-Sen University, Kaohsiung, 80424, Taiwan; National Museum of Marine Biology and Aquarium, Pingtung, 94450, Taiwan.
| |
Collapse
|
121
|
Sousa AA. Impact of soft protein interactions on the excretion, extent of receptor occupancy and tumor accumulation of ultrasmall metal nanoparticles: a compartmental model simulation. RSC Adv 2019; 9:26927-26941. [PMID: 35528561 PMCID: PMC9070572 DOI: 10.1039/c9ra04718b] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2019] [Accepted: 08/11/2019] [Indexed: 12/13/2022] Open
Abstract
Ultrasmall metal nanoparticles (NPs) are next-generation nano-based platforms for in vivo disease diagnosis and treatment. Due to their small size below the kidney filtration threshold and marked resistance to nonspecific serum protein adsorption, ultrasmall NPs can be rapidly excreted through the kidneys and escape liver uptake. However, although ultrasmall particles may be deemed highly resistant to protein adsorption, the real extent of this resistance is not known. Here, a simple compartmental model simulation was therefore implemented to understand how NP behavior in vivo could be modulated by soft, transient NP–plasma protein interactions characterized by dissociation constants in the millimolar range. In Model 1, ultrasmall NPs functionalized with a targeting probe, plasma proteins and target receptors were assumed to co-exist within a single compartment. Simulations were performed to understand the synergistic effect of soft interactions, systemic clearance and NP size on receptor occupancy in the single compartment. The results revealed the existence of a narrow range of ultraweak affinities and optimal particle sizes leading to greater target occupancy. In Model 2, simulations were performed to understand the impact of soft interactions on NP accumulation into a peripheral (tumor) compartment. The results revealed that soft interactions – but not active targeting – enhanced tumor uptake levels when tumor accumulation was limited by ‘fast’ plasma clearance and ‘slow’ vascular extravasation. The simple model presented here provides a basic framework to quantitatively understand the blood and tumor pharmacokinetics of ultrasmall NPs under the influence of transient protein interactions. A compartmental model simulation shows that the blood and tumor pharmacokinetics of ultrasmall metal nanoparticles can be modulated by soft interactions with plasma proteins.![]()
Collapse
Affiliation(s)
- Alioscka A. Sousa
- Department of Biochemistry
- Federal University of São Paulo
- São Paulo
- Brazil
| |
Collapse
|
122
|
Synthesis, antituberculosis studies and biological evaluation of new quinoline derivatives carrying 1,2,4-oxadiazole moiety. Bioorg Med Chem Lett 2018; 29:97-102. [PMID: 30448235 DOI: 10.1016/j.bmcl.2018.11.002] [Citation(s) in RCA: 41] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2018] [Revised: 10/22/2018] [Accepted: 11/02/2018] [Indexed: 11/22/2022]
Abstract
Tuberculosis is the infectious disease caused by mycobacterium tuberculosis (Mtb), responsible for the utmost number of deaths annually across the world. Herein, twenty-one new substituted 1,2,4-oxadiazol-3-ylmethyl-piperazin-1-yl-quinoline derivatives were designed and synthesized through multistep synthesis followed by in vitro evaluation of their antitubercular potential against Mtb WT H37Rv. The compound QD-18 was found to be promising with MIC value of 0.5 µg/ml and QD-19 to QD-21 were also remarkable with MIC value of 0.25 µg/ml. Additionally, we have carried out experiments to confirm the metabolic stability, cytotoxicity and pharmacokinetics of these compounds along with kill kinetics of QD-18. These compounds were found to be orally bioavailable and highly effective. Altogether, these results indicate that QD-18, QD-19, QD-20 and QD-21 are promising lead compounds for the development of a novel chemical class of antitubercular drugs.
Collapse
|
123
|
Takeo E, Shimma S. Development of quantitative imaging mass spectrometry (q
-IMS) for drug visualization using animal tissues. SURF INTERFACE ANAL 2018. [DOI: 10.1002/sia.6537] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Emi Takeo
- Department of Biotechnology, Graduate School of Engineering; Osaka University; Suita 565-0871 Japan
| | - Shuichi Shimma
- Department of Biotechnology, Graduate School of Engineering; Osaka University; Suita 565-0871 Japan
| |
Collapse
|
124
|
Nigade PB, Gundu J, Sreedhara Pai K, Nemmani KVS. Prediction of Tissue-to-Plasma Ratios of Basic Compounds in Mice. Eur J Drug Metab Pharmacokinet 2018; 42:835-847. [PMID: 28194579 DOI: 10.1007/s13318-017-0402-5] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND Majority of reported studies so far developed correlation regression equations using the rat muscle-to-plasma drug concentration ratio (Kp-muscle) to predict tissue-to-plasma drug concentration ratios (Kp-tissues). Use of regression equations derived from rat Kp-muscle may not be ideal to predict the mice tissue-Kps as there are species differences. OBJECTIVES (i) To develop the linear regression equations using mouse tissue-Kps; (ii) to assess the correlation between organ blood flow and/or organ weight with tissue-Kps and (iii) compare the observed tissue-Kps from mice with corresponding predicted tissue-Kps using Richter's rat-Kp specific equations. METHOD Disposition of 12 small molecules were investigated extensively in mouse plasma and tissues after a single oral dose administration. Linear correlation was assessed for each of the tissue with rest of the other tissues, separately for weak and strong bases. RESULT Newly developed regression equations using mice tissue-Kps, predicted 79% data points within twofold. As observed correlation r 2 range was 0.75-0.98 between Kp-muscle and Kp-brain, -spleen, -skin, -liver, -lung, suggesting superior correlation between the tissue-Kps. Order of tissue-Kps, showed that tissue concentrations were directly proportional to the organ blood flow and inversely to the organ weight. Further, the observed tissue-Kps from mice were compared with corresponding predicted tissue-Kps using Richter's rat-Kp specific equations. Overall, 46, 54 and 63% data points were under predicted (<0.5-fold) for liver, spleen and lung, respectively. Whereas 63 and 75% data points were over predicted (>twofold) for skin and brain, respectively. These findings suggest that cross species extrapolation predictability is poor. CONCLUSION All these findings together suggest that mouse specific regression equations developed under controlled experimental conditions could be most appropriate for predicting mouse tissue-Kps for compounds with wide range of volume of distribution.
Collapse
Affiliation(s)
- Prashant B Nigade
- Department of Drug Metabolism and Pharmacokinetics, Lupin Limited (Research Park), Pune, India. .,DMPK, Novel Drug Discovery and Development Department, Lupin Limited (Research Park), 46A/47A, Village Nande, Taluka Mulshi, Pune, 412 115, India.
| | - Jayasagar Gundu
- Department of Drug Metabolism and Pharmacokinetics, Lupin Limited (Research Park), Pune, India
| | - K Sreedhara Pai
- Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, India
| | - Kumar V S Nemmani
- Department of Pharmacology, Lupin Limited (Research Park), Pune, India
| |
Collapse
|
125
|
2-[2-(4-(trifluoromethyl)phenylamino)thiazol-4-yl]acetic acid (Activator-3) is a potent activator of AMPK. Sci Rep 2018; 8:9599. [PMID: 29942003 PMCID: PMC6018554 DOI: 10.1038/s41598-018-27974-1] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2017] [Accepted: 06/06/2018] [Indexed: 02/08/2023] Open
Abstract
AMPK is considered as a potential high value target for metabolic disorders. Here, we present the molecular modeling, in vitro and in vivo characterization of Activator-3, 2-[2-(4-(trifluoromethyl)phenylamino)thiazol-4-yl]acetic acid, an AMP mimetic and a potent pan-AMPK activator. Activator-3 and AMP likely share common activation mode for AMPK activation. Activator-3 enhanced AMPK phosphorylation by upstream kinase LKB1 and protected AMPK complex against dephosphorylation by PP2C. Molecular modeling analyses followed by in vitro mutant AMPK enzyme assays demonstrate that Activator-3 interacts with R70 and R152 of the CBS1 domain on AMPK γ subunit near AMP binding site. Activator-3 and C2, a recently described AMPK mimetic, bind differently in the γ subunit of AMPK. Activator-3 unlike C2 does not show cooperativity of AMPK activity in the presence of physiological concentration of ATP (2 mM). Activator-3 displays good pharmacokinetic profile in rat blood plasma with minimal brain penetration property. Oral treatment of High Sucrose Diet (HSD) fed diabetic rats with 10 mg/kg dose of Activator-3 once in a day for 30 days significantly enhanced glucose utilization, improved lipid profiles and reduced body weight, demonstrating that Activator-3 is a potent AMPK activator that can alleviate the negative metabolic impact of high sucrose diet in rat model.
Collapse
|
126
|
Heller AA, Lockwood SY, Janes TM, Spence DM. Technologies for Measuring Pharmacokinetic Profiles. ANNUAL REVIEW OF ANALYTICAL CHEMISTRY (PALO ALTO, CALIF.) 2018; 11:79-100. [PMID: 29324183 DOI: 10.1146/annurev-anchem-061417-125611] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/16/2023]
Abstract
The creation of a pharmacokinetic (PK) curve, which follows the plasma concentration of an administered drug as a function of time, is a critical aspect of the drug development process and includes such information as the drug's bioavailability, clearance, and elimination half-life. Prior to a drug of interest gaining clearance for use in human clinical trials, research is performed during the preclinical stages to establish drug safety and dosing metrics from data obtained from the PK studies. Both in vivo animal models and in vitro platforms have limitations in predicting human reaction to a drug due to differences in species and associated simplifications, respectively. As a result, in silico experiments using computer simulation have been implemented to accurately predict PK parameters in human studies. This review assesses these three approaches (in vitro, in vivo, and in silico) when establishing PK parameters and evaluates the potential for in silico studies to be the future gold standard of PK preclinical studies.
Collapse
Affiliation(s)
- A A Heller
- Department of Chemistry, Michigan State University, East Lansing, Michigan 48824, USA;
- Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, Michigan 48824, USA
| | - S Y Lockwood
- Department of Biomedical Engineering, Michigan State University, East Lansing, Michigan 48824, USA
- Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, Michigan 48824, USA
| | - T M Janes
- Department of Chemistry, Michigan State University, East Lansing, Michigan 48824, USA;
- Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, Michigan 48824, USA
| | - D M Spence
- Department of Biomedical Engineering, Michigan State University, East Lansing, Michigan 48824, USA
- Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, Michigan 48824, USA
| |
Collapse
|
127
|
Laxman TS, Puttrevu SK, Pradhan R, Mishra A, Verma S, Chhonker YS, Srivastava S, Singh SP, Sashidhara KV, Bhatta RS. Pharmacokinetics, metabolism, bioavailability, tissue distribution and excretion studies of 16α-hydroxycleroda-3, 13(14) Z -dien-15, 16-olide—a novel HMG-CoA reductase inhibitor. Naunyn Schmiedebergs Arch Pharmacol 2018; 391:965-973. [DOI: 10.1007/s00210-018-1518-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2018] [Accepted: 05/22/2018] [Indexed: 10/14/2022]
|
128
|
Domínguez-Avila JA, Wall-Medrano A, Velderrain-Rodríguez GR, Chen CYO, Salazar-López NJ, Robles-Sánchez M, González-Aguilar GA. Gastrointestinal interactions, absorption, splanchnic metabolism and pharmacokinetics of orally ingested phenolic compounds. Food Funct 2018; 8:15-38. [PMID: 28074953 DOI: 10.1039/c6fo01475e] [Citation(s) in RCA: 101] [Impact Index Per Article: 16.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
The positive health effects of phenolic compounds (PCs) have been extensively reported in the literature. An understanding of their bioaccessibility and bioavailability is essential for the elucidation of their health benefits. Before reaching circulation and exerting bioactions in target tissues, numerous interactions take place before and during digestion with either the plant or host's macromolecules that directly impact the organism and modulate their own bioaccessibility and bioavailability. The present work is focused on the gastrointestinal (GI) interactions that are relevant to the absorption and metabolism of PCs and how these interactions impact their pharmacokinetic profiles. Non-digestible cell wall components (fiber) interact intimately with PCs and delay their absorption in the small intestine, instead carrying them to the large intestine. PCs not bound to fiber interact with digestible nutrients in the bolus where they interfere with the digestion and absorption of proteins, carbohydrates, lipids, cholesterol, bile salts and micronutrients through the inhibition of digestive enzymes and enterocyte transporters and the disruption of micelle formation. PCs internalized by enterocytes may reach circulation (through transcellular or paracellular transport), be effluxed back into the lumen (P-glycoprotein, P-gp) or be metabolized by phase I and phase II enzymes. Some PCs can inhibit P-gp or phase I/II enzymes, which can potentially lead to drug-nutrient interactions. The absorption and pharmacokinetic parameters are modified by all of the interactions within the digestive tract and by the presence of other PCs. Undesirable interactions have promoted the development of nanotechnological approaches to promote the bioaccessibility, bioavailability, and bioefficacy of PCs.
Collapse
Affiliation(s)
- J Abraham Domínguez-Avila
- Coordinación de Tecnología de Alimentos de Origen Vegetal, Centro de Investigación en Alimentación y Desarrollo, A.C. Carretera a la Victoria Km 0.6. C.P. 83304, Hermosillo, Sonora, Mexico.
| | - Abraham Wall-Medrano
- Departamento de Ciencias Químico-Biológicas, Instituto de Ciencias Biomédicas, Universidad Autónoma de Ciudad Juárez, Anillo Envolvente del Pronaf y Estocolmo s/n, CP 32310, Cd. Juárez, Chihuahua, Mexico.
| | - Gustavo R Velderrain-Rodríguez
- Coordinación de Tecnología de Alimentos de Origen Vegetal, Centro de Investigación en Alimentación y Desarrollo, A.C. Carretera a la Victoria Km 0.6. C.P. 83304, Hermosillo, Sonora, Mexico.
| | - C-Y Oliver Chen
- Antioxidants Research Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, 711 Washington Street, Boston, Massachusetts 02111, USA.
| | - Norma Julieta Salazar-López
- Departamento de Investigación y Posgrado en Alimentos, Universidad de Sonora, Blvd. Luis Encinas y Rosales S/N Col. Centro, C.P. 83000, Hermosillo, Sonora, Mexico.
| | - Maribel Robles-Sánchez
- Departamento de Investigación y Posgrado en Alimentos, Universidad de Sonora, Blvd. Luis Encinas y Rosales S/N Col. Centro, C.P. 83000, Hermosillo, Sonora, Mexico.
| | - Gustavo A González-Aguilar
- Coordinación de Tecnología de Alimentos de Origen Vegetal, Centro de Investigación en Alimentación y Desarrollo, A.C. Carretera a la Victoria Km 0.6. C.P. 83304, Hermosillo, Sonora, Mexico.
| |
Collapse
|
129
|
Abstract
Many results reported in the biomedical research literature cannot be independently reproduced, undermining the basic foundations of science. This overview is intended for researchers who are committed to improving the quality and integrity of biomedical science by raising awareness of both the sources of irreproducibility, and activities specifically targeted to address the issue. The irreproducibility of biomedical research is due to a variety of factors, known and unknown, that markedly influence experimental outcomes. Among the known factors are inadequate training or mentoring, or experimenter incompetence. These may result in flawed experimental design and execution that reflect a lack of planning, leading to an underpowering of a study, an absence of appropriate controls, selective data analysis, inappropriate statistical analysis, and/or investigator bias or fraud. Another frequently overlooked source of irreproducibility is failure to ensure that the equipment used is performing up to manufacturer specifications. Failure to validate/authenticate the experimental reagents is another source of irreproducibility. These include compounds, cell lines, antibodies, and the animal models used in a study. This overview discusses how a lack of validation of research reagents negatively impact experimental reproducibility, and provides guidelines to avoid these pitfalls. © 2018 by John Wiley & Sons, Inc.
Collapse
Affiliation(s)
- Michael Williams
- Department of Biological Chemistry and Pharmacology, College of Medicine, Ohio State University, Columbus, Ohio
| |
Collapse
|
130
|
Jia Y, Li J, Chen J, Hu P, Jiang L, Chen X, Huang M, Chen Z, Xu P. Smart Photosensitizer: Tumor-Triggered Oncotherapy by Self-Assembly Photodynamic Nanodots. ACS APPLIED MATERIALS & INTERFACES 2018; 10:15369-15380. [PMID: 29652473 DOI: 10.1021/acsami.7b19058] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
Clinical photosensitizers suffer from the disadvantages of fast photobleaching and high systemic toxicities because of the off-target photodynamic effects. To address these problems, we report a self-assembled pentalysine-phthalocyanine assembly nanodots (PPAN) fabricated by an amphipathic photosensitizer-peptide conjugate. We triggered the photodynamic therapy effects of photosensitizers by precisely controlling the assembly and disintegration of the nanodots. In physiological aqueous conditions, PPAN exhibited a size-tunable spherical conformation with a highly positive shell of the polypeptides and a hydrophobic core of the π-stacking Pc moieties. The assembly conformation suppressed the fluorescence and the reactive oxygen species generation of the monomeric photosensitizer molecules (mono-Pc) and thus declined the photobleaching and off-target photodynamic effects. However, tumor cells disintegrated PPAN and released the mono-Pc molecules, which exhibited fluorescence for detection and the photodynamic effects for the elimination of the tumor tissues. The molecular dynamics simulations revealed the various assembly configurations of PPAN and illustrated the assembly mechanism. At the cellular level, PPAN exhibited a remarkable phototoxicity to breast cancer cells with the IC50 values in a low nanomolar range. By using the subcutaneous and orthotopic breast cancer animal models, we also demonstrated the excellent antitumor efficacies of PPAN in vivo.
Collapse
Affiliation(s)
- Yuhua Jia
- State Key Laboratory of Structural Chemistry and CAS Key Laboratory of Design and Assembly of Functional Nanostructures , Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences , Fuzhou , Fujian 350002 , P. R. China
- College of Life Science , Fujian Agriculture and Forestry University , Fuzhou , Fujian 350002 , P. R. China
| | - Jinyu Li
- College of Chemistry , Fuzhou University , Fuzhou , Fujian 350116 , P. R. China
| | - Jincan Chen
- State Key Laboratory of Structural Chemistry and CAS Key Laboratory of Design and Assembly of Functional Nanostructures , Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences , Fuzhou , Fujian 350002 , P. R. China
| | - Ping Hu
- State Key Laboratory of Structural Chemistry and CAS Key Laboratory of Design and Assembly of Functional Nanostructures , Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences , Fuzhou , Fujian 350002 , P. R. China
| | - Longguang Jiang
- College of Chemistry , Fuzhou University , Fuzhou , Fujian 350116 , P. R. China
| | - Xueyuan Chen
- State Key Laboratory of Structural Chemistry and CAS Key Laboratory of Design and Assembly of Functional Nanostructures , Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences , Fuzhou , Fujian 350002 , P. R. China
| | - Mingdong Huang
- State Key Laboratory of Structural Chemistry and CAS Key Laboratory of Design and Assembly of Functional Nanostructures , Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences , Fuzhou , Fujian 350002 , P. R. China
- College of Chemistry , Fuzhou University , Fuzhou , Fujian 350116 , P. R. China
| | - Zhuo Chen
- State Key Laboratory of Structural Chemistry and CAS Key Laboratory of Design and Assembly of Functional Nanostructures , Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences , Fuzhou , Fujian 350002 , P. R. China
| | - Peng Xu
- State Key Laboratory of Structural Chemistry and CAS Key Laboratory of Design and Assembly of Functional Nanostructures , Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences , Fuzhou , Fujian 350002 , P. R. China
| |
Collapse
|
131
|
Abstract
Transporter systems involved in the permeation of drugs and solutes across biological membranes are recognized as key determinants of pharmacokinetics. Typically, the action of membrane transporters on drug exposure to tissues in living organisms is inferred from invasive procedures, which cannot be applied in humans. In recent years, imaging methods have greatly progressed in terms of instruments, synthesis of novel imaging probes as well as tools for data analysis. Imaging allows pharmacokinetic parameters in different tissues and organs to be obtained in a non-invasive or minimally invasive way. The aim of this overview is to summarize the current status in the field of molecular imaging of drug transporters. The overview is focused on human studies, both for the characterization of transport systems for imaging agents as well as for the determination of drug pharmacokinetics, and makes reference to animal studies where necessary. We conclude that despite certain methodological limitations, imaging has a great potential to study transporters at work in humans and that imaging will become an important tool, not only in drug development but also in medicine. Imaging allows the mechanistic aspects of transport proteins to be studied, as well as elucidating the influence of genetic background, pathophysiological states and drug-drug interactions on the function of transporters involved in the disposition of drugs.
Collapse
Affiliation(s)
- Nicolas Tournier
- Imagerie Moléculaire In Vivo, IMIV, CEA, Inserm, CNRS, Univ. Paris-Sud, Université Paris Saclay, CEA-SHFJ, Orsay, France
| | - Bruno Stieger
- Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, 8091 Zurich, Switzerland
| | - Oliver Langer
- Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria; Biomedical Systems, Center for Health & Bioresources, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria; Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.
| |
Collapse
|
132
|
Bangphumi K, Kittiviriyakul C, Towiwat P, Rojsitthisak P, Khemawoot P. Pharmacokinetics of Curcumin Diethyl Disuccinate, a Prodrug of Curcumin, in Wistar Rats. Eur J Drug Metab Pharmacokinet 2018; 41:777-785. [PMID: 26563392 DOI: 10.1007/s13318-015-0308-z] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
BACKGROUND AND OBJECTIVES Curcumin is the major bioactive component of turmeric, but has poor oral bioavailability that limits its clinical applications. To improve the in vitro solubility and alkaline stability, we developed a prodrug of curcumin by succinylation to obtain curcumin diethyl disuccinate, with the goal of improving the oral bioavailability of curcumin. METHODS The in vivo pharmacokinetic profile of curcumin diethyl disuccinate was compared with that of curcumin in male Wistar rats. Doses of curcumin 20 mg/kg intravenous or 40 mg/kg oral were used as standard regimens for comparison with the prodrug at equivalent doses in healthy adult rats. Blood, tissues, urine, and faeces were collected from time zero to 48 h after dosing to determine the prodrug level, curcumin level and a major metabolite by liquid chromatography-tandem spectrometry. RESULTS The absolute oral bioavailability of curcumin diethyl disuccinate was not significantly improved compared with curcumin, with both compounds having oral bioavailability of curcumin less than 1 %. The major metabolic pathway of the prodrug was rapid hydrolysis to obtain curcumin, followed by glucuronidation. Interestingly, curcumin diethyl disuccinate gave superior tissue distribution with higher tissue to plasma ratio of curcumin and curcumin glucuronide in several organs after intravenous dosing at 1 and 4 h. The primary elimination route of curcumin glucuronide occurred via biliary and faecal excretion, with evidence of an entry into the enterohepatic circulation. CONCLUSION Curcumin diethyl disuccinate did not significantly improve the oral bioavailability of curcumin due to first pass metabolism in the gastrointestinal tract. Further studies on reduction of first pass metabolism are required to optimise delivery of curcumin using a prodrug approach.
Collapse
Affiliation(s)
- Kunan Bangphumi
- Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.,Graduate School of Chulalongkorn University, Chulalongkorn University, Bangkok, Thailand
| | - Chuleeporn Kittiviriyakul
- Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.,Graduate School of Chulalongkorn University, Chulalongkorn University, Bangkok, Thailand
| | - Pasarapa Towiwat
- Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.,Chulalongkorn University Drugs and Health Product Innovation Promotion Center, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand
| | - Pornchai Rojsitthisak
- Department of Food and Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.,Chulalongkorn University Drugs and Health Product Innovation Promotion Center, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand
| | - Phisit Khemawoot
- Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand. .,Chulalongkorn University Drugs and Health Product Innovation Promotion Center, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.
| |
Collapse
|
133
|
Costa MB, Picon PD, Sander GB, Cuni HN, Silva CV, Meireles RP, Góes ACMA, Batoreu NM, Maia MDLDS, Albuquerque EM, Matos DCDS, Saura PL. Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers. BMC Pharmacol Toxicol 2018; 19:1. [PMID: 29301580 PMCID: PMC5755306 DOI: 10.1186/s40360-017-0192-z] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2017] [Accepted: 12/15/2017] [Indexed: 11/28/2022] Open
Abstract
BACKGROUND Several countries have used pegylation technology to improve the pharmacokinetic properties of essential drugs. Recently, a novel interferon alfa-2b protein conjugated to four-branched 12 kDa polyethylene glycol molecules was developed jointly between Cuba and Brazil. The aim of this study was to compare the pharmacokinetic properties of BIP48 (pegylated interferon alfa-2b from Bio-Manguinhos/Fiocruz, Brazil) to those of PEGASYS® (commercially available pegylated interferon alfa-2a from Roche Pharmaceutical). METHODS This phase I, single-centre, randomized, double-blind crossover trial enrolled 31 healthy male volunteers aged 19 to 35 who were allocated to two stages, either side of a 5-week wash-out period, with each arm lasting 14 consecutive days after subcutaneous administration of 180 μg of one formulation or the other (study or comparator). The main outcome variable was serum pegylated interferon concentrations in 15 samples collected during the course of the study and tested using an enzyme immunoassay. RESULTS There were no differences between formulations in terms of magnitude or absorption parameters. Analysis of time parameters revealed that BIP48 remained in the body significantly longer than PEGASYS® (Tmax: 73 vs. 54 h [p = 0.0010]; MRT: 133 vs. 115 h [p = 0.0324]; ke: 0.011 vs. 0.013 h(-1) [p = 0.0153]; t1/2: 192 vs. 108 h [p = 0.0218]). CONCLUSION BIP48 showed the expected pharmacokinetic profile for a pegylated product with a branched molecular structure. Compared to PEGASYS®, the magnitude absorption was similar, but time parameters were consistent with slower elimination. Further studies should be conducted to evaluate the clinical implications of these findings. A phase II-III repeated-dose clinical trial is ongoing to study these findings in patients with chronic hepatitis C virus infection. TRIAL REGISTRATION This study is registered on the ClinicalTrials.gov platform (accession number NCT01889849 ). This trial was retrospectively registered in June 2013.
Collapse
Affiliation(s)
- Marisa Boff Costa
- Center of Clinical Research, Hospital de Clínicas de Porto Alegre (HCPA), Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS Brazil
| | - Paulo Dornelles Picon
- Professor of Internal Medicine, Faculdade de Medicina do Rio Grande do Sul (UFRGS), Porto Alegre, RS Brazil
| | - Guilherme Becker Sander
- Professor of Internal Medicine, Faculdade de Medicina do Rio Grande do Sul (UFRGS), Porto Alegre, RS Brazil
| | - Hugo Nodarse Cuni
- Clinical Trials Division, Center for Biological Research, Havana, Cuba
| | | | | | | | | | | | | | | | - Pedro Lopez Saura
- Clinical Trials Division, Center for Biological Research, Havana, Cuba
| |
Collapse
|
134
|
Vostal JG, Gelderman MP, Skripchenko A, Xu F, Li Y, Ryan J, Cheng C, Whitley P, Wellington M, Sawyer S, Hanley S, Wagner SJ. Temperature cycling during platelet cold storage improves in vivo recovery and survival in healthy volunteers. Transfusion 2017; 58:25-33. [DOI: 10.1111/trf.14392] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2017] [Revised: 08/09/2017] [Accepted: 09/01/2017] [Indexed: 11/29/2022]
Affiliation(s)
- Jaroslav G. Vostal
- Laboratory of Cellular HematologyDBCD, OBRR, CBER, FDASilver Spring Maryland
| | | | - Andrey Skripchenko
- Laboratory of Cellular HematologyDBCD, OBRR, CBER, FDASilver Spring Maryland
| | - Fei Xu
- Laboratory of Cellular HematologyDBCD, OBRR, CBER, FDASilver Spring Maryland
| | - Ying Li
- Laboratory of Cellular HematologyDBCD, OBRR, CBER, FDASilver Spring Maryland
| | - Johannah Ryan
- Laboratory of Cellular HematologyDBCD, OBRR, CBER, FDASilver Spring Maryland
| | - Chunrong Cheng
- Office of Biostatistics and EpidemiologyCBER, FDASilver Spring Maryland
| | - Pam Whitley
- Mid‐Atlantic Research FacilityAmerican Red CrossNorfolk Virginia
| | | | - Sherrie Sawyer
- Mid‐Atlantic Research FacilityAmerican Red CrossNorfolk Virginia
| | - Shalene Hanley
- Mid‐Atlantic Research FacilityAmerican Red CrossNorfolk Virginia
| | | |
Collapse
|
135
|
Li C, Liu S, Luo G, Wang G, Zhang B, Nie Q. Comparison of plasma pharmacokinetics of Tanreqing solution between intratracheal aerosolization and intravenous injection in rats. Biomed Chromatogr 2017; 32. [PMID: 29027677 DOI: 10.1002/bmc.4116] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2017] [Revised: 09/26/2017] [Accepted: 10/01/2017] [Indexed: 11/07/2022]
Abstract
A rapid ultra high performance liquid chromatography tandem mass spectrometry method was developed for the simultaneous analysis of baicalin, oroxylin A-7-O-β-d-glucoronide and chlorogenic acid in rats plasma, and applied to comparison of pharmacokinetics of Tanreqing solution between intratracheal aerosolization and intravenous injection. Results of the analytical method validation assay showed high sensitivity, accuracy and suitable recovery. Results of pharmacokinetics showed similar decline phases for baicalin, oroxylin A-7-O-β-d-glucoronide and chlorogenic acid in two different delivery routes. The half-lives of intratracheal aerosolization and intravenous injection were 0.90 and 1.22 h for baicalin, 0.47 and 0.17 h for oroxylin A-7-O-β-d-glucoronide and 0.22 and 0.13 h for chlorogenic acid, and this implies that compounds were retained in the lung for a relatively short time. This study was the first to provide important pharmacokinetics information for traditional Chinese medicine delivery to the lung.
Collapse
Affiliation(s)
- Cui Li
- China Academy of Chinese Medical Sciences, Beijing, China.,Institute of Chinese Material Medica, China Academy of Chinese Medical Sciences, Beijing, China
| | - Siyu Liu
- The Institutes of Biomedical Sciences of Shanghai Medical School, Fudan University, Shanghai, China
| | - Gan Luo
- Institute of Chinese Material Medica, China Academy of Chinese Medical Sciences, Beijing, China
| | - Guohua Wang
- Institute of Chinese Material Medica, China Academy of Chinese Medical Sciences, Beijing, China
| | - Baoxian Zhang
- Institute of Chinese Material Medica, China Academy of Chinese Medical Sciences, Beijing, China
| | - Qixia Nie
- Institute of Chinese Material Medica, China Academy of Chinese Medical Sciences, Beijing, China
| |
Collapse
|
136
|
Zhao L, Xia Z. Bayesian hierarchical model for analyzing multiresponse longitudinal pharmacokinetic data. Stat Med 2017; 36:4816-4830. [DOI: 10.1002/sim.7505] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2016] [Revised: 08/24/2017] [Accepted: 08/28/2017] [Indexed: 11/11/2022]
Affiliation(s)
- Liping Zhao
- Department of Mathematics; Northwest University; Xi'an 710127 China
| | - Zhiming Xia
- Department of Mathematics; Northwest University; Xi'an 710127 China
| |
Collapse
|
137
|
Zuna I, Holt A. ADAM, a hands-on patient simulator for teaching principles of drug disposition and compartmental pharmacokinetics. Br J Clin Pharmacol 2017; 83:2426-2449. [PMID: 28666308 PMCID: PMC5651333 DOI: 10.1111/bcp.13357] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2017] [Revised: 06/13/2017] [Accepted: 06/15/2017] [Indexed: 11/27/2022] Open
Abstract
AIMS To design, construct and validate a pharmacokinetics simulator that offers students hands-on opportunities to participate in the design, administration and analysis of oral and intravenous dosing regimens. METHODS The Alberta Drug Administration Modeller (ADAM) is a mechanical patient in which peristaltic circulation of water through a network of silicone tubing and glass bottles creates a representation of the outcomes of drug absorption, distribution, metabolism and elimination. Changing peristaltic pump rates and volumes in bottles allows values for pharmacokinetic constants to be varied, thereby simulating differences in drug properties and in patient physiologies and pathologies. Following administration of methylene blue dye by oral or intravenous routes, plasma and/or urine samples are collected and drug concentrations are determined spectrophotometrically. The effectiveness of the simulator in enhancing student competence and confidence was assessed in two undergraduate laboratory classes. RESULTS The simulator effectively models one- and two-compartment drug behaviour in a mathematically-robust and realistic manner. Data allow calculation of numerous pharmacokinetic constants, by traditional graphing methods or with curve-fitting software. Students' competence in solving pharmacokinetic problems involving calculations and graphing improved significantly, while an increase in confidence and understanding was reported. CONCLUSIONS The ADAM is relatively inexpensive and straightforward to construct, and offers a realistic, hands-on pharmacokinetics learning opportunity for students that effectively complements didactic lectures.
Collapse
Affiliation(s)
- Ines Zuna
- Department of Pharmacology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
| | - Andrew Holt
- Department of Pharmacology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
| |
Collapse
|
138
|
Chechłacz M, Korytowska N. ZWIĄZKI WIĄŻĄCE SIĘ Z BIAŁKAMI OSOCZA U LUDZI. ZNACZENIE W TERAPII ORAZ METODY OZNACZANIA WOLNEJ FRAKCJI. PROSPECTS IN PHARMACEUTICAL SCIENCES 2017. [DOI: 10.56782/pps.76] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
Wiele substancji endogennych oraz egzogennych wykazuje zdolność do wiązania się z białkami osocza, głównie z ludzką albuminą surowicy oraz α-1-kwaśną glikoproteiną. Substancje te w krwioobiegu występują zarówno w formie wolnej jak i związanej z białkami. Białko posiada na swojej powierzchni miejsca wiązania charakterystyczne dla danego związku, różniące się wielkością, kształtem oraz powinowactwem. Wiązanie z białkami następuje w wyniku oddziaływań hydrofobowych, van der Waalsa oraz elektrostatycznych. Stopień związania z białkami osocza zależy od m.in. obecności stanu zapalnego, występowania chorób nerek i wątroby oraz wieku. Jedynie forma wolna związku jest aktywna biologicznie oraz jest zdolna do pokonywania barier biologicznych. W związku z tym duże znaczenie mają metody pomiaru stężenia frakcji niezwiązanej z białkami w osoczu. Najczęściej stosowana jest dializa równowagowa, uznawana za metodę referencyjną. Inne metody to m.in. ultrafiltracja, ultrawirowanie, mikrodializa, mikroekstrakcja, wysokosprawna analiza czołowa oraz ekstrakcja w punkcie zmętnienia.
Collapse
|
139
|
|
140
|
Comparison of therapeutic responses to an anticancer drug in three stocks of ICR mice derived from three different sources. Lab Anim Res 2017; 33:187-194. [PMID: 28747986 PMCID: PMC5527146 DOI: 10.5625/lar.2017.33.2.187] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2017] [Revised: 06/16/2017] [Accepted: 06/17/2017] [Indexed: 12/30/2022] Open
Abstract
Korl:ICR mice, established by the Korean National Institute of Food and Drug Safety Evaluation (NIFDS), are characterized based on their genetic variation, response to gastric injury, and response to constipation inducers. To compare the inhibitory responses of ICR stocks obtained from three different sources to the anticancer drug cisplatin (Cis), alterations in tumor volume, histopathological structure, and toxicity were examined in Sarcoma 180 tumor-bearing Korl:ICR, A:ICR (USA source), and B:ICR (Japan source) mice treated with low and high concentrations of Cis (L-Cis and H-Cis, respectively). Tumor size and volume were lower in H-Cis-treated mice than in L-Cis-treated mice in all three ICR stocks with no significant differences among stocks. There was a significant enhancement of the necrotizing areas in the histological structures in the L-Cis- and H-Cis-treated groups relative to that in the untreated group. The necrotizing area changes were similar in the Sarcoma 180 tumor-bearing Korl:ICR, A:ICR, and B:ICR mice. However, there were stock-bases differences in the serum biomarkers for liver and kidney toxic effects. In particular, the levels of AST, ALT and BUN increased differently in the three H-Cis-treated ICR stocks, whereas the levels of ALP and CRE were constant. Taken together, the results of the present study indicate that Korl:ICR, A:ICR, and B:ICR mice have similar overall inhibitory responses following Cis treatment of Sarcoma 180-derived solid tumors, although there were some differences in the magnitude of the toxic effects in the three ICR stocks.
Collapse
|
141
|
Xu Q, Liu K, Lin X, Qin Y, Chen L, Cheng J, Zhong M, He Q, Li Y, Wang T, Pan J, Peng M, Yao L, Ji Z. ADMETNet: The knowledge base of pharmacokinetics and toxicology network. J Genet Genomics 2017; 44:273-276. [PMID: 28529076 DOI: 10.1016/j.jgg.2017.04.005] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2016] [Revised: 03/11/2017] [Accepted: 04/29/2017] [Indexed: 10/19/2022]
Affiliation(s)
- Quan Xu
- State Key Laboratory of Stress Cell Biology, School of Life Sciences, Xiamen University, Xiamen 361102, China
| | - Ke Liu
- State Key Laboratory of Stress Cell Biology, School of Life Sciences, Xiamen University, Xiamen 361102, China
| | - Xingming Lin
- State Key Laboratory of Stress Cell Biology, School of Life Sciences, Xiamen University, Xiamen 361102, China
| | - Yangmei Qin
- State Key Laboratory of Stress Cell Biology, School of Life Sciences, Xiamen University, Xiamen 361102, China
| | - Linshan Chen
- State Key Laboratory of Stress Cell Biology, School of Life Sciences, Xiamen University, Xiamen 361102, China
| | - Jiao Cheng
- State Key Laboratory of Stress Cell Biology, School of Life Sciences, Xiamen University, Xiamen 361102, China
| | - Mindong Zhong
- State Key Laboratory of Stress Cell Biology, School of Life Sciences, Xiamen University, Xiamen 361102, China
| | - Qiushun He
- State Key Laboratory of Stress Cell Biology, School of Life Sciences, Xiamen University, Xiamen 361102, China
| | - Yinbo Li
- State Key Laboratory of Stress Cell Biology, School of Life Sciences, Xiamen University, Xiamen 361102, China
| | - Tingwu Wang
- State Key Laboratory of Stress Cell Biology, School of Life Sciences, Xiamen University, Xiamen 361102, China
| | - Jianbo Pan
- State Key Laboratory of Stress Cell Biology, School of Life Sciences, Xiamen University, Xiamen 361102, China
| | - Menglu Peng
- State Key Laboratory of Stress Cell Biology, School of Life Sciences, Xiamen University, Xiamen 361102, China
| | - Lixia Yao
- Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA
| | - Zhiliang Ji
- State Key Laboratory of Stress Cell Biology, School of Life Sciences, Xiamen University, Xiamen 361102, China; The Key Laboratory for Chemical Biology of Fujian Province, Xiamen University, Xiamen 361005, China.
| |
Collapse
|
142
|
Bhateria M, Rachumallu R, Yerrabelli S, Saxena AK, Bhatta RS. Insight into stereoselective disposition of enantiomers of a potent antithrombotic agent, S002-333 following administration of the racemic compound to mice. Eur J Pharm Sci 2017; 101:107-114. [DOI: 10.1016/j.ejps.2017.02.012] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2016] [Revised: 02/06/2017] [Accepted: 02/06/2017] [Indexed: 11/30/2022]
|
143
|
Ali H, Prasad Verma PR, Dubey SK, Venkatesan J, Seo Y, Kim SK, Singh SK. In vitro–in vivo and pharmacokinetic evaluation of solid lipid nanoparticles of furosemide using Gastroplus™. RSC Adv 2017. [DOI: 10.1039/c7ra04038e] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
In this work, we conducted pharmacokinetic studies and established the in vitro and in vivo correlation (IVIVC) of furosemide (FRS) loaded solid lipid nanoparticles (FSLN).
Collapse
Affiliation(s)
- Hasan Ali
- Department of Pharmaceutical Sciences and Technology
- Birla Institute of Technology
- Ranchi-835215
- India
| | | | - Sunil Kumar Dubey
- Department of Pharmacy
- Birla Institute of Technology and Science
- Pilani
- India
| | | | - Youngwan Seo
- Department of Marine Life Sciences
- Korean Maritime and Ocean University
- Busan 49112
- Republic of Korea
| | - Se-Kwon Kim
- Kolmar Korea Co., Ltd
- Seoul
- Republic of Korea
- Department of Marine Life Sciences
- Korean Maritime and Ocean University
| | - Sandeep Kumar Singh
- Department of Pharmaceutical Sciences and Technology
- Birla Institute of Technology
- Ranchi-835215
- India
- Marine Bioprocess Research Centre and Department of Marine Bio-convergence Science
| |
Collapse
|
144
|
Cárdenas PA, Kratz JM, Hernández A, Costa GM, Ospina LF, Baena Y, Simões CMO, Jimenez-Kairuz Á, Aragon M. In vitro intestinal permeability studies, pharmacokinetics and tissue distribution of 6-methylcoumarin after oral and intraperitoneal administration in Wistar rats. BRAZ J PHARM SCI 2017. [DOI: 10.1590/s2175-97902017000116081] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
|
145
|
Marques LM, Callejon DR, Pinto LG, de Campos ML, de Oliveira AR, Vessecchi R, Adhikari A, Shrestha RL, Peccinini RG, Lopes NP. Pharmacokinetic properties, in vitro metabolism and plasma protein binding of govaniadine an alkaloid isolated from Corydalis govaniana Wall. J Pharm Biomed Anal 2016; 131:464-472. [DOI: 10.1016/j.jpba.2016.09.003] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2016] [Revised: 08/30/2016] [Accepted: 09/01/2016] [Indexed: 12/01/2022]
|
146
|
The Role of Chromatography in Alzheimer’s Disease Drug Discovery. ADVANCES IN CHROMATOGRAPHY 2016. [DOI: 10.1201/9781315370385-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
147
|
Blood-brain barrier transport kinetics of the cyclic depsipeptide mycotoxins beauvericin and enniatins. Toxicol Lett 2016; 258:175-184. [DOI: 10.1016/j.toxlet.2016.06.1741] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2016] [Revised: 06/22/2016] [Accepted: 06/24/2016] [Indexed: 11/20/2022]
|
148
|
|
149
|
Quantitative In Vitro and In Vivo Evaluation of Intestinal and Blood-Brain Barrier Transport Kinetics of the Plant N-Alkylamide Pellitorine. BIOMED RESEARCH INTERNATIONAL 2016; 2016:5497402. [PMID: 27493960 PMCID: PMC4947679 DOI: 10.1155/2016/5497402] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/28/2016] [Accepted: 06/05/2016] [Indexed: 12/16/2022]
Abstract
Objective. To evaluate the gut mucosa and blood-brain barrier (BBB) pharmacokinetic permeability properties of the plant N-alkylamide pellitorine. Methods. Pure pellitorine and an Anacyclus pyrethrum extract were used to investigate the permeation of pellitorine through (1) a Caco-2 cell monolayer, (2) the rat gut after oral administration, and (3) the BBB in mice after intravenous and intracerebroventricular administration. A validated bioanalytical UPLC-MS(2) method was used to quantify pellitorine. Results. Pellitorine was able to cross the Caco-2 cell monolayer from the apical-to-basolateral and from the basolateral-to-apical side with apparent permeability coefficients between 0.6 · 10(-5) and 4.8 · 10(-5) cm/h and between 0.3 · 10(-5) and 5.8 · 10(-5) cm/h, respectively. In rats, a serum elimination rate constant of 0.3 h(-1) was obtained. Intravenous injection of pellitorine in mice resulted in a rapid and high permeation of pellitorine through the BBB with a unidirectional influx rate constant of 153 μL/(g·min). In particular, 97% of pellitorine reached the brain tissue, while only 3% remained in the brain capillaries. An efflux transfer constant of 0.05 min(-1) was obtained. Conclusion. Pellitorine shows a good gut permeation and rapidly permeates the BBB once in the blood, indicating a possible role in the treatment of central nervous system diseases.
Collapse
|
150
|
Veryser L, Taevernier L, Joshi T, Tatke P, Wynendaele E, Bracke N, Stalmans S, Peremans K, Burvenich C, Risseeuw M, De Spiegeleer B. Mucosal and blood-brain barrier transport kinetics of the plant N-alkylamide spilanthol using in vitro and in vivo models. Altern Ther Health Med 2016; 16:177. [PMID: 27296455 PMCID: PMC4907212 DOI: 10.1186/s12906-016-1159-0] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2015] [Accepted: 06/03/2016] [Indexed: 12/12/2022]
Abstract
Background N-alkylamides (NAAs) are a large group of secondary metabolites occurring in more than 25 plant families which are often used in traditional medicine. A prominent active NAA is spilanthol. The general goal was to quantitatively investigate the gut mucosa and blood-brain barrier (BBB) permeability pharmacokinetic properties of spilanthol. Methods Spilanthes acmella (L.) L. extracts, as well as purified spilanthol were used to investigate (1) the permeation of spilanthol through a Caco-2 cell monolayer in vitro, (2) the absorption from the intestinal lumen after oral administration to rats, and (3) the permeation through the BBB in mice after intravenous injection. Quantification of spilanthol was performed using a validated bio-analytical UPLC-MS2 method. Results Spilanthol was able to cross the Caco-2 cell monolayer in vitro from the apical-to-basolateral side and from the basolateral-to-apical side with apparent permeability coefficients Papp between 5.2 · 10−5 and 10.2 · 10−5 cm/h. This in vitro permeability was confirmed by the in vivo intestinal absorption in rats after oral administration, where an elimination rate constant ke of 0.6 h−1 was obtained. Furthermore, once present in the systemic circulation, spilanthol rapidly penetrated the blood-brain barrier: a highly significant influx of spilanthol into the brains was observed with a unidirectional influx rate constant K1 of 796 μl/(g · min). Conclusions Spilanthol shows a high intestinal absorption from the gut into the systemic circulation, as well as a high BBB permeation rate from the blood into the brain. Electronic supplementary material The online version of this article (doi:10.1186/s12906-016-1159-0) contains supplementary material, which is available to authorized users.
Collapse
|